wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47731175-880DF3A2-6212-49C2-B9A0-95B8EFE6A108
Q47731175-880DF3A2-6212-49C2-B9A0-95B8EFE6A108
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47731175-880DF3A2-6212-49C2-B9A0-95B8EFE6A108
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
P2860
Q47731175-880DF3A2-6212-49C2-B9A0-95B8EFE6A108
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47731175-880DF3A2-6212-49C2-B9A0-95B8EFE6A108
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8e334aac47a1107dceabefc98d409069a6666d2d
P2860
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.